Management of a dentigerous cyst in a medically compromised geriatric patient: a case report

The Management of a Geriatric Patient Using Dabigatran Therapy on Dentigerous Cyst with Oral Bleeding

Jaw cysts represent a great matter of interest in oral and maxillofacial surgery. Jaw cyst surgery is a common intervention in oral surgery but, in the case of a multidisciplinary patient, the oral surgeon needs to meet with other specialists. A cyst is an epithelium-lined sac containing fluid and/or semisolid material due to epithelial cell proliferation, degeneration, and liquefaction; the hypertonic solution withdraws liquids from the surrounding tissues, while internal pressure exerts an equal strength on the cyst walls. Dentigerous cysts are the second most common odontogenic cysts after radicular cysts, and commonly few or no symptoms are reported. However, the most common diagnosis for dentigerous cyst is represented by eruption of the affected tooth or accidental diagnosis. Commonly, dentigerous cysts may be related to impacted third molars; in the case of impacted third molars and a dentigerous cyst, the tooth should be removed along with the cyst in the same intervention. Mandibular dentigerous cysts are common in children and adults, while dentigerous cysts are a rare neoformation in elderly patients. Treatment usually involves removal of the entire cyst and the associated unerupted tooth. This intervention may be more difficult if the cyst is large, the third molar is in contact with the mandibular nerve, and/or the patient has a medical history that may represent a relative or absolute contraindication. We present the case of a rare symptomatic manifestation of dentigerous cyst in an elderly patient in treatment with dabigatran therapy; for the treatment of dentigerous cysts in the elderly, we suggest a multidisciplinary approach with the use of the histological examination and a careful follow-up.

Hemostatic and Histopathological Effects of Local Mineral Zeolite and Tranexamic Acid in Experimental Femoral Artery Bleeding Model

Background/Aim: This study aimed to evaluate the effect of local zeolite and tranexamic acid application on hemostasis duration and histopathological changes in the experimental bleeding model, created by puncturing femoral arteries in rats.

Material and Methods: A total of 36 Sprague Dawley female rats weighing an average of 240 ± 20 g were used in the study. The three main study groups were the zeolite, zeolite+tranexamic acid, and control groups. Each group was sacrificed on the seventh and fourteenth days of the study, using subgroups for histopathological findings. After piercing the femoral artery of each rat, one gram of the material assigned to the group was applied to the bleeding site after which a 100-gram scale weight was placed on the site for 30 sec intervals, during which temperature was measured. The same sequence of procedures was repeated for the control group, using only standard compression. Statistical analysis was performed using IBM Statistical Package for Social Sciences (SPSS) 15 statistical software. Significance was evaluated at the level of p< 0.05.

Results: The bleeding stop time of the control group was significantly longer than the zeolite and zeolite+tranexamic groups (p< 0.05). There was no statistically significant difference between the zeolite and zeolite+tranexamic groups’ bleeding stop times (p> 0.05) or between the mean wound temperatures of the control and zeolite+tranexamic acid groups when bleeding stopped (p> 0.05).

Conclusions: The effectiveness of the zeolite group and zeolite+tranexamic acid mixture is more than the control group in ensuring bleeding control. Their efficacy has been clearly observed in providing hemostasis. In addition, it has been determined that zeolite tranexamic acid mixture causes less exothermic reaction than zeolite group. We believe that this new formula should be developed and used to guide new studies.

Dental surgery and antiplatelet agents: bleed or die

In patients taking antiplatelet medications who are undergoing dental surgery, physicians and dentists must weigh the bleeding risks in continuing antiplatelet medications versus the thrombotic risks in interrupting antiplatelet medications. Bleeding complications requiring more than local measures for hemostasis are rare after dental surgery in patients taking antiplatelet medications. Conversely, the risk for thrombotic complications after interruption of antiplatelet therapy for dental procedures apparently is significant, although small. When a clinician is faced with a decision to continue or interrupt antiplatelet therapy for a dental surgical patient, the decision comes down to "bleed or die." That is, there is a remote chance that continuing antiplatelet therapy will result in a (nonfatal) bleeding problem requiring more than local measures for hemostasis versus a small but significant chance that interrupting antiplatelet therapy will result in a (possibly fatal) thromboembolic complication. The decision is simple: It is time to stop interrupting antiplatelet therapy for dental surgery.